People · Operator
Named in public records as an officer, director or promoter · active 2010–2013 · Other Technology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Molecular Templates, Inc. | — | Other Technology | Series A | $9.4M | $194.2M | 2013 |
| Ascenta Therapeutics, Inc. | — | Pharmaceuticals | Seed | $1.8M | $68.5M | 2010 |
Louis Bock at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Louis Bock on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Timothy Sullivan | 1 | 16 |
| Michael Powell | 1 | 14 |
| Kevin Lalande | 1 | 8 |
| Casey Cunningham | 1 | 7 |
| Joe Cunningham | 1 | 5 |
| Marc Lippman | 1 | 5 |
| J. Mel Sorensen | 1 | 3 |
| Jason Kim | 1 | 3 |
| Andrew E. Senyei | 1 | 3 |
| Joel Sussman | 1 | 2 |
| Steven Gullans | 1 | 2 |
| Norman Selby | 1 | 2 |
| Larry Witte | 1 | 1 |
| Eric Poma | 1 | 1 |
| Stephen Howard | 1 | 1 |
| Eckard E. Weber | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.